| چکیده انگلیسی مقاله |
Background and Objective: The use of low-molecular-weight, nonpeptidic molecules that degrade the interaction between the p53 protein and its negative regulator MDM2 (Murine- double minute colon 2) is a new therapeutic strategy for treatment of various types of cancer. One of these agents is RITA (reactivation of p53 and induction of tumor cell apoptosis) which binds to p53 protein and inhibits formation of p53-MDM2 complex while induces apoptosis in tumor cells by increasing p53 protein levels. The aim of this study was to assess the possible in vitro apoptotic effects of RITA on pre-B ALL NALM-6 cells. Materials and Methods: NALM-6 cells were treated with different concentrations of RITA at different time intervals. The viability of NALM-6 cells and apoptosis was measured by MTT assay and PI staining, respectively. The level of p53, acetylated p53 as well as cleaved PARP and procaspase-3 were determined by Western blot in RITA-treated cells. The results were analyzed using Paired t test. Results: RITA has cytotoxic effects on NALM-6 cells. Flow cytometry analysis indicated increased apoptotic cells in sub G1 region in treated cells (P < 0.05). The Western blot analysis revealed that protein expression levels of p53, and its acetylation increased in response to RITA. In addition, RITA-induced apoptosis associated with activation of caspase-3 and PARP cleavage. Conclusion: The results of this study showed that RITA induced p53-dependent apoptosis in pre-B ALL NALM-6 cells. Key words: RITA, p53, MDM2, Apoptosis, ALL 1- Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013 381: 1943-55. 2- Schrappe M, Hunger SP, Pui C-H, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. New Eng J Med. 2012 366: 1371-81. 3- Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol. 2009 27: 5175-81. 4- Shah NN, Dave H, Wayne AS. Immunotherapy for pediatric leukemia. Frontiers in Oncology. 2013 3. 5- Bai L, Zhu W-G. p53: structure, function and therapeutic applications. J Cancer Mol. 2006 2: 141-53. 6- Allen P, Newland A, Bustin S. The role of apoptosis (programmed cell death) in haemopoiesis and the immune system. Blood Reviews. 1993 7: 63-73. 7- Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morpho. 2012 45: 115-23. 8- Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013 6: 23. 9- Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences. 1991 88: 5413-7. 10- Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. Journal of Clinical Oncology. 1999 17: 399. 11- Lens D, De Schouwer PJ, Hamoudi RA, Abdul-Rauf M, Farahat N, Matutes E, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997 89: 2015-23. 12- Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene. 1999 18: 7637-43. 13- Roh J-L, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer letters. 2012 325: 35-41. 14- Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors. Nature Medicine. 2004 10: 128-1321. 15- Selivanova G, editor Therapeutic targeting of p53 by small molecules. Seminars in cancer biology 2010: Elsevier. 16- Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Research. 2010 70: 3372-81. 17- Adachi N, So S, Iiizumi S, Nomura Y, Murai K, Yamakawa C, et al. The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination. DNA and Cell Biology. 2006 19 24-25. 18- Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia. 2008 23: 467-76. 19- Saha MN, Yang Y, Chang H. Targeting p53 by small molecule p53 activators in multiple myeloma. J Hematol Oncol. 2012 5(Suppl 1): A7. 20- Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation. The EMBO J. 2002 21: 6236-45. 21- Marine J-C, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death & Differentiation. 2009 17: 93-102. 22- Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. The international journal of biochemistry & cell biology. 2007 39: 1476-82. 23- Kastan MB. Wild-type p53: tumors can't stand it. Cell. 2007 128: 837-40. 24- Saha MN, Jiang H, Mukai A, Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Molecular Cancer Therapeutics. 2010 9: 3041-51. 25- Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell. 200915: 441-53. 26- Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer. 2002 2: 277-88. |